Axial Spondyloarthritis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

$2000

Axial spondylitis is a type of inflammatory arthritis involving the spine and/or sacroiliac joints. Axial spondylitis is strongly related to the presence of the HLA-B27 gene. A genetic test for HLA-B27 is available. The Axial Spondyloarthritis pipeline drugs market research report provides comprehensive information on the therapeutics under development for Axial Spondyloarthritis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases.

Axial Spondyloarthritis Pipeline Drugs Market Segmentation by Targets

The key targets of the Axial Spondyloarthritis pipeline drugs market are Tumor Necrosis Factor, Interleukin 17A, Tyrosine Protein Kinase JAK1, Interleukin 17, Lymphotoxin Alpha, Interleukin 17F, MAP Kinase Activated Protein Kinase 2, and Mitogen Activated Protein Kinase 1.

Axial Spondyloarthritis Pipeline Drugs Market Analysis, by Targets

Axial Spondyloarthritis Pipeline Drugs Market Analysis, by Targets

For more target insights into the Axial Spondyloarthritis pipeline drugs market, download a free report sample

Axial Spondyloarthritis Pipeline Drugs Market Segmentation by Mechanisms of Action

The key mechanisms of action of the axial spondyloarthritis pipeline drugs market are Tumor Necrosis Factor Inhibitor, Interleukin 17A Inhibitor, Tyrosine Protein Kinase JAK1 Inhibitor, Interleukin 17 Inhibitor, Lymphotoxin Alpha Inhibitor, Interleukin 17F Inhibitor, and MAP Kinase Activated Protein Kinase 2 Inhibitor.

Axial Spondyloarthritis Pipeline Drugs Market Analysis, by Mechanisms of Action

Axial Spondyloarthritis Pipeline Drugs Market Analysis, by Mechanisms of ActionFor more mechanisms of action insights into the Axial Spondyloarthritis pipeline drugs market, download a free report sample

Axial Spondyloarthritis Pipeline Drugs Market Segmentation by Routes of Administration

The key routes of administration in the axial spondyloarthritis pipeline drugs market are subcutaneous, oral, intravenous, parenteral, intramuscular, and topical.

Axial Spondyloarthritis Pipeline Drugs Market Analysis, by Routes of Administration

Axial Spondyloarthritis Pipeline Drugs Market Analysis, by Routes of Administration

For more routes of administration insights into the Axial Spondyloarthritis pipeline drugs market, download a free report sample

Axial Spondyloarthritis Pipeline Drugs Market Segmentation by Molecule Types

The key molecule types in the Axial Spondyloarthritis pipeline drugs market are monoclonal antibody, small molecule, fusion protein, monoclonal antibody conjugated, antisense RNAi oligonucleotide, protein, and recombinant protein.

Axial Spondyloarthritis Pipeline Drugs Market Analysis, by Molecule Types

Axial Spondyloarthritis Pipeline Drugs Market Analysis, by Molecule TypesFor more molecule type insights into the Axial Spondyloarthritis pipeline drugs market, download a free report sample

Axial Spondyloarthritis Pipeline Drugs Market - Competitive Landscape

Some of the leading companies in the axial spondyloarthritis pipeline drugs market are Jiangsu Hengrui Medicine Co Ltd, AbbVie Inc, Akeso Inc, Avesthagen Ltd, Biocad, Bioviz Technologies Pvt Ltd, Bristol-Myers Squibb Co, and DNX Biopharmaceuticals Inc.

Axial Spondyloarthritis Pipeline Drugs Market Analysis, by Companies

Axial Spondyloarthritis Pipeline Drugs Market Analysis, by Companies

To know more about the companies in the Axial Spondyloarthritis pipeline drugs market, download a free report sample

Axial Spondyloarthritis Pipeline Drugs Market Report Overview

Key Targets Tumor Necrosis Factor, Interleukin 17A, Tyrosine Protein Kinase JAK1, Interleukin 17, Lymphotoxin Alpha, Interleukin 17F, MAP Kinase Activated Protein Kinase 2, and Mitogen Activated Protein Kinase 1
Key Mechanism of Actions Tumor Necrosis Factor Inhibitor, Interleukin 17A Inhibitor, Tyrosine Protein Kinase JAK1 Inhibitor, Interleukin 17 Inhibitor, Lymphotoxin Alpha Inhibitor, Interleukin 17F Inhibitor, and MAP Kinase Activated Protein Kinase 2 Inhibitor
Key Routes of Administration Subcutaneous, Oral, Intravenous, Parenteral, Intramuscular, and Topical
Key Molecule Types Monoclonal Antibody, Small Molecule, Fusion Protein, Monoclonal Antibody Conjugated, Antisense RNAi Oligonucleotide, Protein, and Recombinant Protein
Leading Companies Jiangsu Hengrui Medicine Co Ltd, AbbVie Inc, Akeso Inc, Avesthagen Ltd, Biocad, Bioviz Technologies Pvt Ltd, Bristol-Myers Squibb Co, and DNX Biopharmaceuticals Inc

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Axial Spondyloarthritis (Musculoskeletal Disorders).
  • The pipeline guide reviews pipeline therapeutics for Axial Spondyloarthritis (Musculoskeletal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several development stages ranging from pre-registration to discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products, including product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Axial Spondyloarthritis (Musculoskeletal Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Axial Spondyloarthritis (Musculoskeletal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Axial Spondyloarthritis (Musculoskeletal Disorders)

Reasons to Buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Axial Spondyloarthritis (Musculoskeletal Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Axial Spondyloarthritis (Musculoskeletal Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

3SBio Inc
AbbVie Inc
Akeso Inc
AstraZeneca Plc
Avesthagen Ltd
Beijing Eastern Biotech Co Ltd
Bio-Thera Solutions Ltd
Biocad
Biogen Inc
Bioviz Technologies Pvt Ltd
BioXpress Therapeutics SA
Boehringer Ingelheim International GmbH
Bristol-Myers Squibb Co
Celltrion Inc
Clover Biopharmaceuticals Ltd
DNX Biopharmaceuticals Inc
Dyadic International Inc
Eli Lilly and Co
Enzene Biosciences Ltd
Foshan Rexie Biotechnology Co Ltd
FunPep Co Ltd
Genrix (Shanghai) Biopharmaceutical Co Ltd
Huabo Biopharm (Shanghai) Co Ltd
Hualan Biological Engineering Inc
Iltoo Pharma
Immunwork Inc
Izana Bioscience Ltd
Jiangsu Carephar Pharmaceutical Co Ltd
Jiangsu Hengrui Medicine Co Ltd
JiangSu Qyuns Therapeutics Co Ltd
Johnson & Johnson
Livzon Pharmaceutical Group Co Ltd
Luye Pharma Group Ltd
Lynk Pharmaceutical Hangzhou Co Ltd
Mabpharm Ltd
MoonLake Immunotherapeutics
Mycenax Biotech Inc
NeuClone Pty Ltd
Nimbus Therapeutics LLC
North China Pharmaceutical Group New Drug Research and Development Co Ltd
Novartis AG
Outlook Therapeutics Inc
Pharmapraxis
PKU V-Ming (Hefei) Biologics Co Ltd
Qilu Pharmaceutical Co Ltd
Sandoz International GmbH
Shandong Danhong Pharmaceutical Co Ltd
Shanghai Junshi Bioscience Co Ltd
Shanghai Novamab Biopharmaceuticals Co Ltd
Siam Bioscience Co Ltd
SinoCelltech Group Ltd
siRNAgen Therapeutics Corp
Suzhou Zelgen Biopharmaceutical Co Ltd
Tianjin Hemay Pharmaceutical Co Ltd
UCB SA
Valin Technologies Ltd
Wuhan Institute of Biological Products Co Ltd
XinThera Inc
Zhejiang Yatai Pharmaceutical Co Ltd

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Axial Spondyloarthritis – Overview

Axial Spondyloarthritis – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Axial Spondyloarthritis – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Axial Spondyloarthritis – Companies Involved in Therapeutics Development

Axial Spondyloarthritis – Drug Profiles

Axial Spondyloarthritis – Dormant Projects

Axial Spondyloarthritis – Discontinued Products

Axial Spondyloarthritis – Product Development Milestones

Featured News & Press Releases

Aug 17, 2022: NICE Recommends RINVOQ (upadacitinib) as a treatment option for active ankylosing spondylitis (AS) in adults

Aug 08, 2022: Lilly’s Taltz (ixekizumab) now available in new, citrate-free formulation to reduce injection site pain for improved patient experience

Jul 29, 2022: RINVOQ (upadacitinib) approved by European Commission as an oral treatment for adults with active non-radiographic axial spondyloarthritis

Jul 27, 2022: Mabpharm announces approval of clinical trial application of CMAB015 by the National Medical Products Administration of China

Jul 21, 2022: Sandoz Supplemental Biologics License Application accepted by US FDA for biosimilar Hyrimoz (adalimumab-adaz) high concentration formulation (HCF)

Jul 20, 2022: Health Canada approves AbbVie’s RINVOQ® (upadacitinib) for the treatment of adults with active ankylosing spondylitis

Jun 27, 2022: CHMP recommends approval of Upadacitinib (RINVOQ) for the treatment of adults with active non-radiographic axial spondyloarthritis

Jun 01, 2022: AbbVie Presents Positive Results from Phase 3 SELECT-AXIS 2 Trials of Upadacitinib (RINVOQ®) in Patients with Axial Spondyloarthritis at EULAR 2022

Jun 01, 2022: AbbVie Presents Positive Results from Phase 3 SELECT-AXIS 2 Trials of Upadacitinib (RINVOQ®) in Patients with Axial Spondyloarthritis at EULAR 2022

May 23, 2022: First presentations of phase 3 data for Bimekizumab across the full spectrum of Axial Spondyloarthritis to be Shared at EULAR 2022

May 02, 2022: FDA grants approval for AbbVie’s Rinvoq to treat ankylosing spondylitis

Apr 11, 2022: Celltrion Healthcare announces the availability of Yuflyma, a high-concentration, low-volume, citrate-free, and latex-free Humira (adalimumab) biosimilar in Canada

Jan 20, 2022: Lynk doses first patient in Phase II ankylosing spondylitis drug trial

Jan 18, 2022: Positive top-line results for bimekizumab in phase 3 non-radiographic axial spondyloarthritis study

Jan 07, 2022: AbbVie submits applications for Upadacitinib (RINVOQ) in non-radiographic axial spondyloarthritis to U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA)

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Table

List of Tables

Number of Products under Development for Axial Spondyloarthritis, 2022

Number of Products under Development by Companies, 2022

Products under Development by Companies, 2022

Number of Products by Stage and Target, 2022

Number of Products by Stage and Mechanism of Action, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Axial Spondyloarthritis – Dormant Projects, 2022

Axial Spondyloarthritis – Dormant Projects, 2022 (Contd..1)

Axial Spondyloarthritis – Dormant Projects, 2022 (Contd..2)

Axial Spondyloarthritis – Dormant Projects, 2022 (Contd..3)

Axial Spondyloarthritis – Discontinued Products, 2022

Figures

List of Figures

Number of Products under Development for Axial Spondyloarthritis, 2022

Number of Products under Development by Companies, 2022

Number of Products by Top 10 Targets, 2022

Number of Products by Stage and Top 10 Targets, 2022

Number of Products by Top 10 Mechanism of Actions, 2022

Number of Products by Stage and Top 10 Mechanism of Actions, 2022

Number of Products by Top 10 Routes of Administration, 2022

Number of Products by Stage and Top 10 Routes of Administration, 2022

Number of Products by Top 10 Molecule Types, 2022

Number of Products by Stage and Top 10 Molecule Types, 2022

Frequently asked questions

Axial Spondyloarthritis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update thematic reports
Currency USD
$2,000

Can be used by individual purchaser only

$6,000

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Axial Spondyloarthritis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update in real time.

  • Access a live Axial Spondyloarthritis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.